Angiotensin II receptor blockers in patients with systemic right ventricular dysfunction

Trial Profile

Angiotensin II receptor blockers in patients with systemic right ventricular dysfunction

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2012

At a glance

  • Drugs Valsartan (Primary)
  • Indications Right ventricular dysfunction
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 02 Feb 2011 Last checked against ISRCTN: Current Controlled Trials.
    • 01 Nov 2010 Rationale and trial design were presented in an article in the American heart journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top